-
Mashup Score: 0Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia - 4 year(s) ago
Shilatifard and colleagues demonstrate gain-of-function mutations in ASXL1 that drive BAP1 stabilization and widespread epigenetic changes in myeloid neoplasms, and develop a chemical inhibitor with therapeutic potential for ASXL1-altered leukemia.
Source: Nature CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response - 4 year(s) ago
Müller-Tidow and colleagues demonstrate that hotspot DNMT3A mutations found in clonal hematopoiesis and acute myeloid leukemia render cancer cells sensitive to the DNMT1 inhibitor azacitidine through focal DNA demethylation, viral mimicry and interferon activation.
Source: Nature CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response | Nature Cancer https://t.co/IwDtEArIeI
-
-
Mashup Score: 0Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer - 4 year(s) ago
Diehn and colleagues report that assaying circulating DNA in patients receiving chemoradiation therapy for non-small-cell lung cancer could identify the patients most likely to benefit from consolidation immunotherapy.
Source: Nature CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
@n8pennell Getting there! This further validates the studies below demonstrating the strong prognostic value of ctDNA MRD in localized NSCLC. Furthermore, at least retrospectively, systemic therapy appears to be able to improve outcomes of some ctDNA MRD+ pts (https://t.co/sQP6ZGOeBs) https://t.co/xwIjGGri3C
-
-
Mashup Score: 10A global effort to understand the riddles of COVID-19 and cancer - 4 year(s) ago
Cancer has found a formidable foil in COVID-19, and this has brought to the fore the early concerns that COVID-19 could have a deeper impact on oncology patients. Two studies now provide insights into the enigma surrounding the determinants of the worsening of COVID-19 symptoms in patients with cancer.
Source: Nature CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
🚨 Dr. Julio Frenk expertly reconciles the parallels and interplay between #COVID and #cancer & touches down upon determinants of mortality @NatureCancer @ASCO @OncoAlert & mentions @GlopesMd global work ! @COVID19nCCC #ASCO21 https://t.co/L90bYDYfGO https://t.co/isE1lIGtiX
-
-
Mashup Score: 7Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas - 4 year(s) ago
Platten and colleagues find that tryptophan metabolism by myeloid cells contributes to immunosuppressive microenvironment uniquely in IDH-mutant gliomas, which can be overcome by inhibiting this pathway in murine tumor models.
Source: Nature CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In IDH-mutant gliomas, changes cancer cell metabolism alter tryptophan metabolism in infiltrating myeloid cells, blocking their differentiation & promoting an immature phenotype that drives tolerogenic alignment of the TME, thus preventing T cell responses https://t.co/A0oGOYS8K2
-
-
Mashup Score: 2Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients - 4 year(s) ago
Amrolia and colleagues characterize the clonal origins of long-term persistent CAR T cells from the CARPALL trial using low-affinity CAR T cells mediating long-term anti-leukemic control in patients through TSCM-mediated responses.
Source: Nature CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
This paper from Nature Cancer by Biasco et al. may help identify patients at risk of early loss of CAR T cells and highlight the critical role of T memory stem cells in mediating early anti-leukemic responses and long-term surveillance by CAR T cells. https://t.co/L6SUqBUrX0
-
-
Mashup Score: 5Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients - 4 year(s) ago
Amrolia and colleagues characterize the clonal origins of long-term persistent CAR T cells from the CARPALL trial using low-affinity CAR T cells mediating long-term anti-leukemic control in patients through TSCM-mediated responses.
Source: Nature CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An analysis of CAR gene integration sites indicates that clonal expansion of T memory stem cells determines early anti-leukaemic responses and long-term CAR T cell persistence in patients: https://t.co/SNAnXDezG4 #ImmunoOnc #hemeonc #leusm #lymsm
-
-
Mashup Score: 21Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response - 4 year(s) ago
Müller-Tidow and colleagues demonstrate that hotspot DNMT3A mutations found in clonal hematopoiesis and acute myeloid leukemia render cancer cells sensitive to the DNMT1 inhibitor azacitidine through focal DNA demethylation, viral mimicry and interferon activation.
Source: Nature CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
⭐️ONLINE NOW @NatureCancer: "Hotspot DNMT3A mutations in #ClonalHematopoiesis and #AML sensitize cells to azacytidine via viral mimicry response", a fantastic study by Carsten Müller-Tidow @dblipka1 and co @DKFZ Find it here! https://t.co/4WS9BbxzUu https://t.co/pdlITZFKNA https://t.co/QEIFk4t7mj
-
-
Mashup Score: 22Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia - 4 year(s) ago
Shilatifard and colleagues demonstrate gain-of-function mutations in ASXL1 that drive BAP1 stabilization and widespread epigenetic changes in myeloid neoplasms, and develop a chemical inhibitor with therapeutic potential for ASXL1-altered leukemia.
Source: Nature CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
⭐️DO NOT MISS - ONLINE NOW @NatureCancer: "#Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated #leukemia" - a *fantastic* study by Ali Shilatifard and Co @NorthwesternU Find it here: https://t.co/AekvpQetD0 https://t.co/4tiTamrgGP https://t.co/tnkZnuBgH2
-
-
Mashup Score: 8Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients - 4 year(s) ago
Amrolia and colleagues characterize the clonal origins of long-term persistent CAR T cells from the CARPALL trial using low-affinity CAR T cells mediating long-term anti-leukemic control in patients through TSCM-mediated responses.
Source: Nature CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Ashishsaroha79: https://t.co/BfMLhjxWjR. @AlbeenaDr @DrGauravNarula @CTCTC_tmc
-
Frameshift mutations in ASXL1, originally proposed to be LOF, encode truncated GOF proteins that increase BAP1 stability, recruitment to chromatin & activation of a pro-leukaemic transcriptional signature, which can be counteracted by novel BAP1 inhibitors https://t.co/TAL38kjQTd